KRMD
Fallen FavouriteKORU Medical Systems, Inc. · Healthcare · United States · $146M cap · $737K/day traded
$3.89 +23.1% · close 11 Nov · scored 12 Nov
Score up 6.1 since 11 Nov: Momentum up 9 after a 23% price rise.
Fallen Favourite: A good business, still expensive, and its momentum is weak.
As of 12 Nov 2026, the MoatMap Score for KORU Medical Systems, Inc. (KRMD) is 35/100, ranked against 25,000+ stocks in 38 markets (Quality 58, Value 21, Momentum 47, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT KORU MEDICAL SYSTEMS, INC.
Read
KORU Medical Systems, Inc. designs, manufactures, and markets innovative medical devices and supplies for subcutaneous infusion, including the FREEDOM Infusion System. The company holds a strong position in the niche market of subcutaneous infusion, offering specialized and patient-friendly solutions that enhance convenience and adherence for chronic care patients. KORU Medical is a specialized healthcare device company, focusing on improving the quality of life for patients requiring regular subcutaneous infusions through its innovative delivery systems.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.9M | 28.5M | 33.6M | 41.1M | 13.8% | 45.1M | 48.0M | 56.3M | 17.0% |
| EPS | -0.19 | -0.30 | -0.13 | -0.06 | — | -0.04 | — | — | — |
| Shares | 45.4M | 45.7M | 46.0M | 46.4M | +2.0% | 45.9M | — | — | — |
| Debt | 4.9M | 4.4M | 4.0M | 3.5M | -10.8% | 3.3M | — | — | — |
| Equity | 31.3M | 20.4M | 16.8M | 17.0M | -18.4% | — | — | — | — |
| Op CF | -5.4M | -4.9M | -0.3M | 0.5M | — | 1.4M | — | — | — |
| Inv CF | -2.8M | -0.8M | -1.3M | -0.9M | — | — | — | — | — |
| Fin CF | 0.3M | -0.2M | -0.2M | -0.2M | — | — | — | — | — |
No new 52-week low for 5 weeks, 36% above that low, but not back above a rising 50-day average.
Swung more than 69% of stocks we rank over the past year (volatility 55% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KRMD are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| KRMD | KORU Medical Systems, Inc.(you) | $146M | 35 |
| OSUR | OraSure Technologies, Inc. | $285M | 42 |
| DXR | Daxor Corporation | $54M | 36 |
| POCI | Precision Optics Corporation, Inc. | $52M | 35 |
| ANGO | AngioDynamics, Inc. | $520M | 35 |
| STXS | Stereotaxis, Inc. | $102M | 7 |
| SMTI | Sanara MedTech Inc. | $301M | 61 |
| STAA | STAAR Surgical Company | $1.1B | 33 |
| KMTS | Kestra Medical Technologies, Ltd. | $1.7B | 31 |
| AZTA | Azenta, Inc. | $1.6B | 48 |
Peer medians: ROE -31.0% · P/E 25.9x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.